A Phase 2 clinical trial evaluating AL102 in T-cell acute lymphoblastic leukemia (T-ALL)
Latest Information Update: 19 Aug 2022
At a glance
- Drugs BMS 986115 (Primary)
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 19 Aug 2022 New trial record
- 15 Aug 2022 According to an Ayala Pharmaceuticals media release, the company plans to begin an investigator-initiated Phase 2 clinical trial evaluating AL102 in R/R T-ALL around year-end.